Why would they amortize this sum to be amortized over 24 month so in the financials it only shows
a positive of $21,000 each month? This purposely makes it look like BGMD has no funds when in fact
they do have these sum payments from Abbott.
Who are they trying to decieve?
Cash as of DEC 2015 $1.5 million. Cash as of end of March 1 million.
Looks like they are burning $500,000 per quarter.
Revenue for all of 2015
(about 1.4 million) dropped by 50% from 2014. 2015 EXTRA Revenue even with automated sales
by Abbott for about 6 months and the .5 million advanced payment from Abbott
(only 21,000 per month amortized over 24 months). amounted to only about $61,000.
The increase revenue from automated sales isn't any where near enough to offset
the overall decrease in revenue. ($61000 compared to 1.3 million.
By July they may have $500,000 left and maybe six months revenue including from Abbott
(assuming they get the other $500,000 from Abbott in June) for the first half of 2016 will
be maybe $800,000
Salaries are about $1 million per year.
The company is toast.
Only hope is a sale of the company to Abbott and that will not happen.
But this is all just all manipulation
just like previous range bound
cycles. Stock is dead and range bound.
Share price won't improve as long as daily short volume is up around 80%. At this point a lot more supply than demand. Since no news shorts will have their way.
I agree, but now it doesn't depend on management but on ABT's ability to deliver. If BG can reach breakeven sometime this yr, or about $3 million revenu, then they will survive and SP should go back up. If not, then it's BK later this yr.
You still don't get it do you? Management is not able to monetize this thing no matter how many
studies come out. They couldn't do it in Europe and couldn't do it in the US. We had this conversation
more than a year ago. Forget??
Gal-3 is not able to distinguish between HFrEF and HFpEF patients. However it is related to diastolic dysfunction severity and LV stiffness in HFpEF. Gal-3 demonstrates a prognostic role independently from renal dysfunction in subjects with HFpEF.
Copyright © 2016 Elsevier B.V. All rights reserved.
Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction.
Almost half of patients with acute heart failure have preserved ejection fraction (HFpEF). HFpEF is a diagnostic challenge using traditional investigation tools; Galectin-3 (Gal-3) is an emerging biomarker useful in individuals at risk for HF. The aim of our study is to analyse the relation and prognostic value of Gal-3, BNP and renal dysfunction in patients with HFpEF compared to patients with reduced ejection fraction (HFrEF).
We enrolled 98 patients with acute heart failure (AHF) and measured Gal-3, BNP, and estimated glomerular filtration rate (eGFR) within 12h of hospital admission. On the basis of echocardiographic findings we divided our sample into two groups: patients with HFrHF (ejection fraction 50%). Patients were followed up at 6months.
No differences in Gal-3 levels were found in the two subgroups (HFrEF: 19.5±5.1ng/mL; HFpEF: 20.5±8.7, p=0.56). Gal-3 was inversely related to renal dysfunction (LogGal-3 vs eGFR: r=-0.30, p=0.01) but did not correlate with LogBNP levels (r=0.07, p=0.55). Gal-3 was associated with more advanced diastolic dysfunction in HFpEF (p=0.009). In addition LogGal-3 was related to diastolic LV stiffness (all patients: r=0.45, p 1.30 was related to poor outcome independently from renal dysfunction and other risk factors only in HFpEF (univariate HR 23.98 [3.03-89.45]; p
Want a winner? Check out ultimatestockalertss (search em) if you are looking for small cap stocks
before the big run. He has alerted me to a bunch of stocks before they took off.
Open google now and search for UltimateStockAlertss. You will be glad you did. Their plays are
killing it and the last trade I took from then helped me make 21% in 2 days. Cant complain about
There is nothing to sell.
The company is a shell with one licence
that they have not been able to monetize.
So the value of the license is virtually nothing!
I don't know, but if I hey can reach breakeven, then yes at that point in time. This new Major study 6000 patients may be what they need to compliment BioImage data ie Serial Gal3. Or sell the damn company and let ABT file with this new data(90% of work for 2nd indication is done). No one knows what they are up to. I just see good studies being published and ABT still marketing Gal-3, but like the rest of us no clue on sales progression.
You think they are going to file 2nd indication. Man, you are just too optimistic.
I only hope and that ABT can deliver. If they manage to get 2nd indication cleared with new data, then that may help as well, but not counting on it, just on ABT to allow BG to reach breakeven and profitablity eventually. They may fail or succeed. It's anyone's guess now